Ferring Makes Foray Into Gene Therapy With FKD Pact

The Swiss company's CMO Klaus Dugi tells Scrip that getting the rights to a late-stage bladder cancer gene therapy from Finland's FKD highlights the transformation that Ferring is undergoing.

Gene therapy
Ferring has high hopes for bladder cancer gene therapy • Source: Shutterstock

Fresh from announcing a deal to acquire the USA's Rebiotix Inc. and moving into the microbiome drug development space, Ferring Pharmaceuticals AS is also targeting the hot area of gene therapy with a late-stage licensing deal for a novel bladder cancer treatment from Finland's FKD Therapies OY.

The Swiss firm has taken the option, dependent on US approval, to secure global commercialization rights to rAd-IFN/Syn3 (nadofaragene firadenovec/Syn3),...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category